Daniel Groth
Allergy & Immunology · Seattle, WANPI 1821476979
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,031 of the $2,272 with a category attached, or 89.4%. 19 manufacturers reported payments, led by AstraZeneca at 40.6% of the total. 2025 is the largest year on record at $923, 3.6 times the $253 reported in 2021.
Across 77 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$921
- Sanofi$259
- Sanofi-aventis U.S. LLC$195
- Takeda Pharmaceuticals U.S.A., Inc.$179
- Regeneron Healthcare Solutions, Inc.$119
- Amgen$112
- plus $485 from 13 others
What the payments were for
- Consulting fees$452%
- Food & beverage$2,03189%
- Education$1959%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $921 |
| Sanofi | 9 | $259 |
| Sanofi-aventis U.S. LLC | 2 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $179 |
| Regeneron Healthcare Solutions, Inc. | 4 | $119 |
| Amgen | 5 | $112 |
| GSK | 4 | $68 |
| Biocryst US Sales Co., LLC | 2 | $56 |
| Alk-abello, Inc | 3 | $54 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $49 |
| ADMA Biomanufacturing LLC | 2 | $45 |
| Pfizer | 2 | $45 |
| Novartis | 1 | $33 |
| Grifols USA, LLC | 1 | $27 |
| Lilly USA, LLC | 1 | $27 |
| Blueprint Medicines Corporation | 1 | $25 |
| Pharming Healthcare, Inc. | 1 | $22 |
| Organon | 1 | $21 |
| Kaleo, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,272 in reported general payments places this provider in the 60th percentile of 81 allergy & immunology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $337,259 |
| Dupixent SyringeDupilumab | 22 | $89,360 |
| Arnuity ElliptaFluticasone Furoate | 28 | $11,549 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $11,308 |
| Qvar RedihalerBeclomethasone Dipropionate | 18 | $9,550 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $8,291 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $6,904 |
| DuleraMometasone/Formoterol | 13 | $6,029 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $4,060 |
| AlvescoCiclesonide | 11 | $3,465 |
| Epinephrine | 16 | $2,722 |
| Olopatadine Hcl | 22 | $2,305 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $2,229 |
| Azelastine Hcl | 45 | $1,936 |
| Fluticasone Propionate | 53 | $1,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $179 | $337,25913 claims |
| GSKArnuity Ellipta, Breo Ellipta | $68 | $22,85758 claims |
| AstraZenecaSymbicort | $921 | $8,29118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 81 allergy & immunology providers in Washington.
Other allergy & immunology in Seattle
- Frank VirantSeattle$107K
- Leonard AltmanSeattle$81K
- Daniel PetroniSeattle$68K
- Rahool DaveSeattle$42K
- Matthew AltmanSeattle$37K
- Gabriel MendozaSeattle$16K
- Kelly ColasSeattle$14K
- Jing Yi SunSeattle$11K
- Paul WilliamsSeattle$7K
- Susan XieSeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.